{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cytarabine+liposome+injection", "query": { "intervention": "cytarabine liposome injection" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 52, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cytarabine+liposome+injection&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-30T20:25:26.914Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03555955", "title": "A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematologic Malignancy", "Acute Myeloid Leukemia", "Acute Lymphocytic Leukemia", "Acute Lymphoblastic Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "CPX-351", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2018-11-20", "completion_date": "2021-05-26", "has_results": false, "last_update_posted_date": "2021-07-22", "last_synced_at": "2026-09-30T20:25:26.914Z", "location_count": 11, "location_summary": "Washington D.C., District of Columbia • Atlanta, Georgia • Westwood, Kansas + 8 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03555955" }, { "nct_id": "NCT04049539", "title": "Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Blasts More Than 5 Percent of Bone Marrow Nucleated Cells", "Persistent Disease", "Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Liposome-encapsulated Daunorubicin-Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 28, "start_date": "2021-01-29", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-09-30T20:25:26.914Z", "location_count": 2, "location_summary": "Sacramento, California • Columbus, Ohio", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04049539" }, { "nct_id": "NCT03226418", "title": "Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Acute Myeloid Leukemia", "Secondary Acute Myeloid Leukemia", "Therapy-Related Acute Myeloid Leukemia" ], "interventions": [ { "name": "Cytarabine", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Liposome-encapsulated Daunorubicin-Cytarabine", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "glasdegib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 75, "start_date": "2017-07-07", "completion_date": "2024-10-01", "has_results": true, "last_update_posted_date": "2026-03-10", "last_synced_at": "2026-09-30T20:25:26.914Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03226418" }, { "nct_id": "NCT00299182", "title": "Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "AMG 531", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2006-03", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2021-09-21", "last_synced_at": "2026-09-30T20:25:26.914Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00299182" }, { "nct_id": "NCT03904251", "title": "CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myelogenous Leukemia" ], "interventions": [ { "name": "Gemtuzumab Ozogamicin", "type": "DRUG" }, { "name": "Liposome-encapsulated Daunorubicin-Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2019-07-18", "completion_date": "2023-10-25", "has_results": false, "last_update_posted_date": "2023-11-18", "last_synced_at": "2026-09-30T20:25:26.914Z", "location_count": 5, "location_summary": "Los Angeles, California • Orange, California • Sacramento, California + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03904251" }, { "nct_id": "NCT06788756", "title": "L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Acute Myeloid Leukaemia (AML)" ], "interventions": [ { "name": "Placebo in combination with Cytarabine Injection", "type": "DRUG" }, { "name": "Liposomal Annamycin Injection in combination with Cytarabine Injection", "type": "DRUG" }, { "name": "Liposomal Annamycin for Injection in combination with Cytarabine Injection.", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Moleculin Biotech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 312, "start_date": "2025-03-12", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-09-30T20:25:26.914Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Miami, Florida • Augusta, Georgia + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Miami", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Morristown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06788756" }, { "nct_id": "NCT02269579", "title": "Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia (AML)", "Acute Lymphoblastic Leukemia (ALL)", "Myelodysplastic Syndrome (MDS)" ], "interventions": [ { "name": "CPX-351", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 0, "start_date": "2015-04", "completion_date": "2017-06", "has_results": false, "last_update_posted_date": "2018-03-14", "last_synced_at": "2026-09-30T20:25:26.914Z", "location_count": 5, "location_summary": "Los Angeles, California • Gainesville, Florida • Indianapolis, Indiana + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02269579" }, { "nct_id": "NCT04526288", "title": "CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Myelodysplastic Syndrome With Excess Blasts-2", "Myeloid Neoplasm" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Liposome-encapsulated Daunorubicin-Cytarabine", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2021-08-09", "completion_date": "2023-08-27", "has_results": true, "last_update_posted_date": "2024-05-23", "last_synced_at": "2026-09-30T20:25:26.914Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04526288" }, { "nct_id": "NCT05365035", "title": "A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes", "Myeloproliferative Chronic Myelomonocytic Leukemia" ], "interventions": [ { "name": "Cladribine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2022-09-23", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-09-30T20:25:26.914Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05365035" }, { "nct_id": "NCT03844997", "title": "Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "AML" ], "interventions": [ { "name": "Palcociclib", "type": "DRUG" }, { "name": "CPX-351", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sudipto Mukherjee, MD, PhD, MPH", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 35, "start_date": "2019-06-06", "completion_date": "2024-01-24", "has_results": true, "last_update_posted_date": "2025-05-31", "last_synced_at": "2026-09-30T20:25:26.914Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03844997" } ] }